Biovest International, Inc. Release: National Cancer Institute Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study
6/7/2012 10:05:43 AM
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID® lymphoma vaccine clinical trial. The results (detailed in Abstract #2528), reported in a poster presented by the NCI, demonstrated that vaccination following rituximab combination chemotherapy induced nearly universal T-cell immune responses, the elevation of which strongly correlated with overall survival and time-to-next treatment benefits in patients with mantle cell lymphoma (MCL), a highly aggressive form of B-cell non-Hodgkin’s lymphoma.
comments powered by